Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
A comprehensive study integrating global and individual data reveals that adherence to the Planetary Health Diet Index (PHDI) provides significant protection against metabolic dysfunction-associated steatotic liver disease (MASLD), highligh
This article explores the groundbreaking link between the Planetary Health Diet Index (PHDI) and reduced risks of metabolic dysfunction-associated steatotic liver disease (MASLD), offering evidence-based insights for personal health and env
The NAFLDiet trial reveals that while both anti-lipogenic LCPUFA and Healthy Nordic Diets reduce liver fat, the Nordic diet offers superior benefits for weight loss, glycemic control, and systemic inflammation in patients with type 2 diabet
This review synthesizes findings from the MAESTRO-NASH trial, highlighting that Resmetirom’s efficacy is maintained alongside GLP-1 RAs and SGLT2 inhibitors, while being significantly enhanced by concurrent weight loss.
The SYNERGY-NASH trial demonstrates that Tirzepatide significantly improves MASH resolution and liver fibrosis. This effect is driven by substantial weight loss, improved glycemic control, and liver fat normalization, highlighting a transfo
Researchers have identified AXL expression as a critical biomarker in colorectal cancer. While it usually signals treatment resistance, a new study reveals that AXL-high tumors with KRAS mutations respond significantly better to immunothera
The randomized CAVE-2 GOIM trial demonstrates that while adding avelumab to cetuximab rechallenge does not improve survival in metastatic colorectal cancer, liquid biopsy-based genomic hyper-selection identifies a subgroup of patients with
A Phase Ib/II trial evaluating the combination of XL888 (an HSP90 inhibitor) and pembrolizumab in metastatic pancreatic adenocarcinoma found that while the regimen was safe and induced systemic immune modulation, it failed to alter the tumo
Researchers have developed ICyM2, a carrier-free nanoaggregate that combines mitochondrial phototherapy with STING activation. This platform effectively remodels the dense pancreatic cancer stroma, triggers immunogenic cell death, and syner
A phase 1/2 trial demonstrates the safety and clinical potential of nonengineered, multiantigen-targeted T cell therapy for pancreatic ductal adenocarcinoma, highlighting durable T cell persistence and antigen spreading as key correlates of
GSK has announced positive Phase III results for Bepirovirsen, an antisense oligonucleotide that achieves functional cure in chronic hepatitis B patients. By targeting viral RNA and HBsAg, the drug offers a finite treatment path, potentiall
A nationwide target trial emulation reveals that SGLT2 inhibitors significantly reduce major adverse cardiovascular events and mortality compared to other oral antidiabetics in patients with concurrent T2DM and MASLD, with benefits partiall
A Phase 3 randomized clinical trial finds no significant difference in 5-year overall survival between neoadjuvant chemoradiotherapy and surgery with adjuvant therapy for locally advanced ESCC, emphasizing the need for personalized treatmen
The phase 1b/2 MORPHEUS-EC trial demonstrates that adding the anti-TIGIT antibody tiragolumab to atezolizumab and chemotherapy significantly improves objective response rates (67.7%) in patients with previously untreated, locally advanced o
The Phase 3 SKYSCRAPER-08 trial demonstrates that adding the anti-TIGIT tiragolumab and anti-PD-L1 atezolizumab to chemotherapy significantly extends overall survival and progression-free survival in patients with treatment-naive, unresecta
A Phase 3 trial demonstrates that cendakimab significantly reduces dysphagia days and improves histologic and endoscopic markers in patients with eosinophilic esophagitis, offering a targeted therapeutic approach for this chronic type 2 inf
A post hoc analysis of the LEAN-TIME trial reveals that integrating gut microbiome and metabolomic data with clinical phenotypes significantly improves the prediction of weight loss and regain, offering a framework for precision weight mana
A global genomic study of Helicobacter pylori reveals that mutations in 23S rRNA and gyrA predict antibiotic resistance with 100% sensitivity, signaling the end of empirical therapy in favor of genotype-based personalized treatment.
A randomized phase 2 trial demonstrates that primary prophylaxis with peg-GCSF significantly reduces grade 3-4 and febrile neutropenia in patients with unresectable pancreatic cancer receiving mFOLFIRINOX, while improving patient-reported q
The SOMA.GUT-RCT investigated a targeted psychological intervention for IBS and UC. While the primary 3-month endpoint showed no significant symptom reduction compared to standard care, exploratory data revealed significant psychological im
Open language-specific specialty feeds and department pages.